CF PharmTech executes HK$0.11 million share buy-back; treasury stock rises to 637,000 shares

Bulletin Express04-27 18:23

CF PharmTech, Inc. disclosed a repurchase of 5,500 H-shares on 27 April 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange on the same date.

The shares were bought back on-market at prices ranging from HK$20.58 to HK$20.90, with a volume-weighted average cost of HK$20.73 per share. The aggregate consideration amounted to approximately HK$0.11 million.

Following the transaction, the company’s issued share capital (excluding treasury shares) decreased from 301.59 million to 301.59 million shares, while treasury shares increased from 631,500 to 637,000. The buy-back represents 0.0018% of the company’s outstanding shares prior to the transaction, leaving the total issued share count unchanged at 302.22 million.

The repurchase falls under the mandate approved by shareholders on 16 December 2025, which authorises the company to buy back up to 30.22 million shares. Including the latest transaction, CF PharmTech has repurchased 637,000 shares under this mandate, equivalent to 0.21% of the issued share base on the mandate date.

The company confirmed that the repurchase complied with Hong Kong Main Board Listing Rules and that a 30-day moratorium on new share issues or treasury share disposals will apply until 27 May 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1113173013?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-27 18:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113173013","market":"us","top_or_hot":-1,"title":"CF PharmTech executes HK$0.11 million share buy-back; treasury stock rises to 637,000 shares","media":"Bulletin Express","content":"<p>CF PharmTech, Inc. disclosed a repurchase of 5,500 H-shares on 27 April 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange on the same date.</p>\n<p>The shares were bought back on-market at prices ranging from HK$20.58 to HK$20.90, with a volume-weighted average cost of HK$20.73 per share. The aggregate consideration amounted to approximately HK$0.11 million.</p>\n<p>Following the transaction, the company’s issued share capital (excluding treasury shares) decreased from 301.59 million to 301.59 million shares, while treasury shares increased from 631,500 to 637,000. The buy-back represents 0.0018% of the company’s outstanding shares prior to the transaction, leaving the total issued share count unchanged at 302.22 million.</p>\n<p>The repurchase falls under the mandate approved by shareholders on 16 December 2025, which authorises the company to buy back up to 30.22 million shares. Including the latest transaction, CF PharmTech has repurchased 637,000 shares under this mandate, equivalent to 0.21% of the issued share base on the mandate date.</p>\n<p>The company confirmed that the repurchase complied with Hong Kong Main Board Listing Rules and that a 30-day moratorium on new share issues or treasury share disposals will apply until 27 May 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CF PharmTech executes HK$0.11 million share buy-back; treasury stock rises to 637,000 shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCF PharmTech executes HK$0.11 million share buy-back; treasury stock rises to 637,000 shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-27 18:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CF PharmTech, Inc. disclosed a repurchase of 5,500 H-shares on 27 April 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange on the same date.</p>\n<p>The shares were bought back on-market at prices ranging from HK$20.58 to HK$20.90, with a volume-weighted average cost of HK$20.73 per share. The aggregate consideration amounted to approximately HK$0.11 million.</p>\n<p>Following the transaction, the company’s issued share capital (excluding treasury shares) decreased from 301.59 million to 301.59 million shares, while treasury shares increased from 631,500 to 637,000. The buy-back represents 0.0018% of the company’s outstanding shares prior to the transaction, leaving the total issued share count unchanged at 302.22 million.</p>\n<p>The repurchase falls under the mandate approved by shareholders on 16 December 2025, which authorises the company to buy back up to 30.22 million shares. Including the latest transaction, CF PharmTech has repurchased 637,000 shares under this mandate, equivalent to 0.21% of the issued share base on the mandate date.</p>\n<p>The company confirmed that the repurchase complied with Hong Kong Main Board Listing Rules and that a 30-day moratorium on new share issues or treasury share disposals will apply until 27 May 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02652","symbol_name":"长风药业","start_time":0,"source_url":"","article_id":"1113173013","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113173013","pubTimestamp":1777285432,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CF PharmTech, Inc. disclosed a repurchase of 5,500 H-shares on 27 April 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange on the same date. The shares were...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02652":"长风药业"},"translate_title":"CF PharmTech执行11万港元股份回购；库存股增至637,000股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1},"content_text":"CF PharmTech, Inc. disclosed a repurchase of 5,500 H-shares on 27 April 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange on the same date.\nThe shares were bought back on-market at prices ranging from HK$20.58 to HK$20.90, with a volume-weighted average cost of HK$20.73 per share. The aggregate consideration amounted to approximately HK$0.11 million.\nFollowing the transaction, the company’s issued share capital (excluding treasury shares) decreased from 301.59 million to 301.59 million shares, while treasury shares increased from 631,500 to 637,000. The buy-back represents 0.0018% of the company’s outstanding shares prior to the transaction, leaving the total issued share count unchanged at 302.22 million.\nThe repurchase falls under the mandate approved by shareholders on 16 December 2025, which authorises the company to buy back up to 30.22 million shares. Including the latest transaction, CF PharmTech has repurchased 637,000 shares under this mandate, equivalent to 0.21% of the issued share base on the mandate date.\nThe company confirmed that the repurchase complied with Hong Kong Main Board Listing Rules and that a 30-day moratorium on new share issues or treasury share disposals will apply until 27 May 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1113173013","isCrawlerRequest":true}